Drug Type Chemical drugs |
Synonyms- |
Target |
Mechanism Nrf2 inhibitors(Nuclear factor erythroid 2-related factor 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Arpeggio Biosciences, Inc.Startup |
Active Organization Arpeggio Biosciences, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Preclinical | US | Arpeggio Biosciences, Inc.Startup | 08 Apr 2024 |